

What is Femring? A complete guide to this estrogen vaginal ring — what it treats, how to use it, dosage options, who should avoid it, and cost in 2026.
Femring is a flexible vaginal ring that delivers Estradiol Acetate, a form of estrogen, directly into your body over 3 months. It's FDA-approved to treat moderate-to-severe hot flashes and vaginal atrophy caused by menopause.
What sets Femring apart from other vaginal estrogen products is that it delivers systemic levels of estrogen — meaning it doesn't just work locally in the vagina. It raises estrogen levels throughout your body, treating both vaginal symptoms and vasomotor symptoms (hot flashes and night sweats).
This guide covers everything you need to know about Femring in 2026: what it's used for, how to take it, who should avoid it, and what it costs.
Femring is a brand-name prescription medication made by Millicent Pharma. It belongs to a class of drugs called estrogens and is used as hormone replacement therapy (HRT) for postmenopausal women.
The active ingredient is Estradiol Acetate, which your body converts into estradiol — the primary form of estrogen your ovaries produced before menopause. By restoring estrogen levels, Femring relieves the symptoms that come with declining hormones.
Unlike Estring (a different vaginal ring that provides only low-dose local estrogen), Femring delivers enough estrogen to reach the bloodstream and treat whole-body symptoms. For a detailed comparison, see our article on alternatives to Femring.
Femring is FDA-approved for two conditions:
Because Femring provides systemic estrogen, it's particularly useful for women who need relief from both vaginal and whole-body menopausal symptoms — all from a single product that you replace every 3 months.
Some providers may also consider it for genitourinary syndrome of menopause (GSM), a broader term that covers vaginal, urinary, and sexual symptoms related to estrogen decline.
Femring is designed to be simple and low-maintenance:
Important notes:
Femring comes in two strengths:
Your doctor will typically start with the 0.05 mg/day ring and increase only if needed. The goal is always to use the lowest effective dose for the shortest time necessary.
For more on how the medication works inside your body, see our article on how Femring works.
Femring is not right for everyone. It carries a boxed warning (the FDA's most serious safety alert) and is contraindicated in the following situations:
The boxed warning specifically highlights increased risks of:
If you still have your uterus, your doctor will prescribe a progestin alongside Femring to reduce endometrial cancer risk.
For a full breakdown of side effects, read our guide on Femring side effects.
Femring is a brand-name medication with no generic available as of 2026. That makes it expensive:
There are ways to reduce the cost:
For a detailed breakdown of all savings options, see our complete Femring savings guide.
Femring is a unique option in the menopause treatment landscape. It combines the convenience of a 3-month vaginal ring with systemic estrogen delivery, making it a good fit for women who need relief from both hot flashes and vaginal symptoms.
Like all hormone therapy, it comes with real risks and isn't right for everyone. The best approach is an honest conversation with your doctor about your symptoms, medical history, and goals.
If you have a Femring prescription and need help finding it in stock, medfinder.com can help you locate pharmacies near you. You can also learn about how to find a doctor who prescribes Femring if you're still looking for a provider.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.